Department of Biochemistry, Section of Medicine and Pharmacy, University of Pavia, Italy.
Nat Rev Endocrinol. 2011 Jun 14;7(9):540-57. doi: 10.1038/nrendo.2011.81.
A new paradigm has emerged for osteogenesis imperfecta as a collagen-related disorder. The more prevalent autosomal dominant forms of osteogenesis imperfecta are caused by primary defects in type I collagen, whereas autosomal recessive forms are caused by deficiency of proteins which interact with type I procollagen for post-translational modification and/or folding. Factors that contribute to the mechanism of dominant osteogenesis imperfecta include intracellular stress, disruption of interactions between collagen and noncollagenous proteins, compromised matrix structure, abnormal cell-cell and cell-matrix interactions and tissue mineralization. Recessive osteogenesis imperfecta is caused by deficiency of any of the three components of the collagen prolyl 3-hydroxylation complex. Absence of 3-hydroxylation is associated with increased modification of the collagen helix, consistent with delayed collagen folding. Other causes of recessive osteogenesis imperfecta include deficiency of the collagen chaperones FKBP10 or Serpin H1. Murine models are crucial to uncovering the common pathways in dominant and recessive osteogenesis imperfecta bone dysplasia. Clinical management of osteogenesis imperfecta is multidisciplinary, encompassing substantial progress in physical rehabilitation and surgical procedures, management of hearing, dental and pulmonary abnormalities, as well as drugs, such as bisphosphonates and recombinant human growth hormone. Novel treatments using cell therapy or new drug regimens hold promise for the future.
成骨不全症已出现新的范式,被认为是一种与胶原相关的疾病。更为常见的常染色体显性遗传型成骨不全症是由Ⅰ型胶原的主要缺陷引起的,而常染色体隐性遗传型成骨不全症则是由与Ⅰ型前胶原相互作用的蛋白缺乏引起的,这些蛋白对于翻译后修饰和/或折叠是必需的。导致显性成骨不全症的机制因素包括细胞内应激、胶原与非胶原蛋白相互作用的中断、基质结构受损、异常的细胞-细胞和细胞-基质相互作用以及组织矿化。隐性成骨不全症是由胶原脯氨酰 3-羟化酶复合物的三个组成部分之一的缺乏引起的。3-羟化的缺失与胶原螺旋的修饰增加有关,这与胶原折叠延迟一致。隐性成骨不全症的其他原因包括胶原伴侣 FKBP10 或 Serpin H1 的缺乏。鼠模型对于揭示显性和隐性成骨不全症骨发育不良的共同途径至关重要。成骨不全症的临床管理是多学科的,包括在物理康复和手术方面取得了实质性进展,以及在听力、牙齿和肺部异常以及药物(如双膦酸盐和重组人生长激素)方面的管理。使用细胞疗法或新药物方案的新治疗方法为未来带来了希望。